Ventyx Biosciences reports data from ulcerative colitis drug trial

US-based biopharmaceutical company Ventyx Biosciences has reported positive data from a Phase II clinical trial of VTX002 for the treatment of active ulcerative colitis (UC).

The placebo-controlled, double-blind trial assessed the safety and efficacy of two oral doses of the S1P1 receptor modulator, VTX002.

Patients with moderate-to-severely active UC received 30mg and 60mg of VTX002 orally once a day for 13 weeks.